Cassano 2002a.

Methods	Eight‐week, double‐blind, randomised, multicentre study.
Participants	Outpatients meeting DSM‐IV criteria for major depression (no patients with bipolar disorder) with a minimum score of 18 on the Hamilton rating scale for depression (HDRS). Age range: 18‐75 years.
Interventions	Paroxetine: 139 participants. Amisulpride: 138 participants. Paroxetine dose range: 20 mg/day. Amisulpride dose range: 50 mg/day. Benzodiazepine or hypnotic given at a stable dose were permitted.
Outcomes	HDRS, Montgomery and Asberg Depression Rating Scale (MADRS), Clinical Global Impression (CGI). Total dropout, dropout due to inefficacy, dropout due to side effects, number of patients experiencing at least one side effect, side‐effect profile.
Notes	Funding: amisulpride manufacturer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Less than 20% of the allocated patients to both of the intervention arms dropped out during the study. The primary efficacy analysis was performed on the Per Protocol (PP) population that included all randomized patients fully compliant with the protocol during the active treatment period and having at least one evaluation of the primary endpoint after baseline. Consistency of results was assessed in the Intention‐to‐treat (ITT) population. For patients not completing the trial the Last Observation Carried Forward (LOCF) was analysed.
Selective reporting (reporting bias)	High risk	Side effects reported only if statistically significant.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.